Trust Co. of Vermont Purchases 13,841 Shares of Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 20th, 2023

Trust Co. of Vermont boosted its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 4.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 307,780 shares of the biopharmaceutical company’s stock after acquiring an additional 13,841 shares during the quarter. Trust Co. of Vermont’s holdings in Pfizer were worth $12,557,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Lam Group Inc. bought a new position in shares of Pfizer during the fourth quarter valued at about $25,000. Worth Asset Management LLC bought a new position in shares of Pfizer during the first quarter valued at about $29,000. My Personal CFO LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $32,000. Mendota Financial Group LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $33,000. Finally, Delos Wealth Advisors LLC grew its stake in shares of Pfizer by 100.0% during the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 400 shares during the last quarter. Institutional investors own 67.80% of the company’s stock.

Insider Activity

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The stock was bought at an average cost of $38.58 per share, for a total transaction of $38,580.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $231,480. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PFE shares. Morgan Stanley cut their target price on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Monday, April 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Pfizer in a research note on Wednesday, May 17th. Barclays cut their target price on Pfizer from $43.00 to $40.00 in a research note on Wednesday, May 3rd. UBS Group cut their target price on Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. Finally, StockNews.com started coverage on Pfizer in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $47.33.

Pfizer Price Performance

PFE stock opened at $40.06 on Tuesday. The firm has a 50 day moving average price of $38.92 and a 200-day moving average price of $42.95. Pfizer Inc. has a 52-week low of $36.17 and a 52-week high of $54.93. The firm has a market capitalization of $226.15 billion, a price-to-earnings ratio of 7.89, a PEG ratio of 1.33 and a beta of 0.64. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.11 and a current ratio of 1.37.

Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The firm had revenue of $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. During the same period last year, the business earned $1.62 earnings per share. The business’s revenue was down 28.8% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 3.35 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 9th. Stockholders of record on Friday, May 12th were issued a dividend of $0.41 per share. The ex-dividend date was Thursday, May 11th. This represents a $1.64 annualized dividend and a dividend yield of 4.09%. Pfizer’s payout ratio is 32.28%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.